Sonoma Pharmaceuticals Analyst Ratings
Sonoma Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Sonoma Pharmaceuticals (SNOA) rating was a initiated with a price target of $0.00 to $3.25. The current price Sonoma Pharmaceuticals (SNOA) is trading at is $0.92, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 253.26% | Ladenburg Thalmann | → $3.25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 253.26% | 拉登堡塔爾曼 | → 3.25 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Sonoma Pharmaceuticals (SNOA)?
索諾瑪製藥（SNOA）的目標價格是多少？
The latest price target for Sonoma Pharmaceuticals (NASDAQ: SNOA) was reported by Ladenburg Thalmann on September 5, 2023. The analyst firm set a price target for $3.25 expecting SNOA to rise to within 12 months (a possible 253.26% upside). 1 analyst firms have reported ratings in the last year.
拉登堡塔爾曼於2023年9月5日公佈了索諾瑪製藥（納斯達克股票代碼：SNOA）的最新目標股價。該分析公司將目標股價定爲3.25美元，預計SNOA將在12個月內上漲至253.26％（可能上漲253.26％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for Sonoma Pharmaceuticals (SNOA)?
索諾瑪製藥（SNOA）的最新分析師評級是多少？
The latest analyst rating for Sonoma Pharmaceuticals (NASDAQ: SNOA) was provided by Ladenburg Thalmann, and Sonoma Pharmaceuticals initiated their buy rating.
索諾瑪製藥（納斯達克股票代碼：SNOA）的最新分析師評級由拉登堡·塔爾曼提供，索諾瑪製藥公司啓動了買入評級。
When is the next analyst rating going to be posted or updated for Sonoma Pharmaceuticals (SNOA)?
索諾瑪製藥（SNOA）的下一份分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonoma Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonoma Pharmaceuticals was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與索諾瑪製藥的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。索諾瑪製藥的最新評級是在2023年9月5日提交的，因此你應該預計下一個評級將在2024年9月5日左右公佈。
Is the Analyst Rating Sonoma Pharmaceuticals (SNOA) correct?
分析師對索諾瑪製藥（SNOA）的評級是否正確？
While ratings are subjective and will change, the latest Sonoma Pharmaceuticals (SNOA) rating was a initiated with a price target of $0.00 to $3.25. The current price Sonoma Pharmaceuticals (SNOA) is trading at is $0.92, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的索諾瑪製藥（SNOA）評級最初的目標股價爲0.00美元至3.25美元。索諾瑪製藥（SNOA）目前的交易價格爲0.92美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
